Rachel Dods

Rachel Dods

Auto-generated profile, based on publicly available information

Rachel Dods

BicycleTx Ltd

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CRCatherine E. Rowland
Catherine E. Rowland
HNHector Newman
Hector Newman
TMTazmin T. Martin
Tazmin T. Martin
RDRachel Dods
Rachel Dods
NBNikolaos Bournakas
Nikolaos Bournakas
MDMichael J. Dawson
Michael J. Dawson
Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of β-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of novel, bicyclic peptide (Bicycle ® ) inhibitors of E. coli PBP3 ( Ec PBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent a novel non-β-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors.